Federal opportunity · Solicitation
ClosedRequest for Proposals (RFP) - BARDA Vaccine Medical Countermeasures for Pandemic Influenza Preparedness & Response
75A50126R00001_RFP_NPIVS_27 · Health and Human Services, Department of · SAM.gov
Closed. Responses were due Oct 30, 2026, 5:00 PM ET.
- Responses due
- Oct 30, 2026, 5:00 PM ET
- Posted
- Aug 17, 2026
- NAICS code
- 541714 · Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- None
- Place of performance
- Washington, DC
- Notice type
- Solicitation
- Solicitation number
- 75A50126R00001_RFP_NPIVS_27
- Official notice
- View on SAM.gov →
Similar open opportunities
- Quantitative Analysis of Longitudinal MR ImagesHealth and Human Services, Department of · Due Nov 9, 2026 · 2 days left
- DNA Sequencing ServiceHealth and Human Services, Department of · Due Nov 12, 2026 · 5 days left
- Simulation-augmented, Real-time Platform Adaptive Seamless Trials (SURPASS)Health and Human Services, Department of · Due Nov 30, 2026 · 24 days left
- Pre-Clinical Models of Infectious DiseasesHealth and Human Services, Department of · Due Dec 7, 2026 · 31 days left
- UNifying Imaging with QUantum Entanglement (UNIQUE) Innovative Solutions Opening (ISO)Health and Human Services, Department of · Due Dec 15, 2026 · 39 days left
- FY27 FDA Broad Agency Announcement (BAA) for Advanced Research and Development of Regulatory ScienceHealth and Human Services, Department of · Due Jan 22, 2027 · 77 days left
What the agency was buying
BARDA seeks Contractor(s) to support the continuation of the Vaccine Medical Counermeasures (MCM's) for Pandemic Influenza Preparedness and Response Program. Contractors will furnish all the necessary services, qualified personnel, materials, supplies, equipment and facilities (U.S. facilities preferred) not otherwise provided by the USG as needed to provide MCMs, such as vaccines, antigens, and adjuvants, for pandemic preparedness and response or as required in response to a public health emergency; produce antigen and vaccines against influenza virus or other viruses with pandemic potential as required by BARDA; produce antigens, adjuvants, and/or vaccines to support USG efforts to further improve influenza vaccines (for which feasibility data is available); and support rapid regulatory decisions and manufacturing readiness by generating and submitting to FDA all relevant data (e.g., analytical, nonclinical, clinical, and/or chemistry, manufacturing, and controls (CMC)), including data generated during interpandemic periods. Mandatory Qualification Requirements: To be eligible for award, the Offeror must produce vaccines against influenza and influenza strains with pandemic potential; must demonstrate a successful experience in the manufacturing of influenza vaccine by: 1. Holding a U.S. influenza vaccine license; or 2. Have developed an influenza vaccine as evidenced by: a. Submission of a Biologics License Application (BLA) for seasonal or pandemic influenza vaccine Please see full solicitation details and proposal submission instructions detailed in attachments 01-19 of this notice.
From the official notice on SAM.gov.